We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. 

With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients. 

Actio Biosciences, Inc.

Will we see you at #BiocomGPIC? Actio CEO and Co-Founder, David B. Goldstein, Ph.D. will take the presenter’s stage on Wednesday, February 28th at 3:45 p.m. PST to talk about Actio and our pursuit to develop life-changing treatments that target underlying shared biology between rare and common diseases. 

At Actio, our people are our driving force. With unique experiences and an overwhelming drive to identify therapies for rare diseases, each member of our team exemplifies our commitment to our core values - including a dedication to scientific rigor. 
 
Meet our associate director, Shelby Gough, an extraordinary leader, who works with her team to de-risk biology and identify high-value targets of interest that can be translated into medicines that make an impact on patients in need. Learn more about Shelby's work and how she and her team strive for scientific rigor every day. 

It’s a pleasure to welcome Samuel Collins, MBBS, Ph.D., MBA as our chief medical officer. As a trained pediatric physician, Dr. Collins joins us with more than 20 years of experience in academia and industry, with a focus in rare diseases and pediatrics. 

Dr. Collins will be pivotal in overseeing all aspects of our clinical development and medical and regulatory affairs for our pipeline of precision medicines. We’re thrilled to add his expertise to our team as we work to bring meaningful medicines from one to many. 

Read more from the announcement below.

Euro

U.S. Server Location

Jason Fuller

Nina Kjellson

George Golumbeski

Alex Tkachenko

David Goldstein

Co-Founder & Chief Executive Officer

Samuel Collins

Chief Medical Officer

University of California Alumni Founded Companies

California Companies With Less Than $1B in Revenue (Top 10K)

San Diego Companies With Fewer Than 1000 Employees (Top 10K)

United States Early Stage Companies (Top 10K)

Actio Biosciences involves in the development of precision medicines for homogenous rare patient populations. They develop a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver medicines for all patients.

Canaan Partners

Droia Ventures

Series A - Actio Biosciences

San Diego

California

United States

North America

Actio Biosciences

Actio Biosciences to Participate in Upcoming October Investor Conferences

Actio Biosciences welcomes Dr. Emil Kakkis to its Board of Directors

Renowned Rare-Disease Drug Developer Emil Kakkis, M.D., Ph.D., to Join Actio Biosciences Board of Directors

Actio Biosciences welcomes Dr. Ben Cravatt to its Board of Directors

Actio Biosciences Appoints Ben Cravatt, Ph.D., to Board of Directors

Laboratory jobs | Bachelors Degree, Full time

Biotechnology Laboratory jobs in San Diego | by Relevance

Biotechnology Science/R&D jobs in San Diego | Full time

Sr. Research Associate-Medicinal Chemistry job with Actio Biosciences, Inc. | 2879504

Actio Biosciences Appoints Samuel Collins, MBBS, Ph.D., MBA, as Chief Medical Officer as Company Advances Multiple Precision Medicine Programs Toward Clinical Development

A small molecule program targeting TRPV4 mutations for the treatment of Charcot-Marie-Tooth disease type 2C and other serious bone diseases.

A proprietary database used to identify relevant disease targets and understand their function in disease for drug discovery and development.

A collaboration to develop and implement new transgenic models of rare disease pathways for target evaluation and phenotype analysis.

An upcoming program aimed at evaluating treatments for genetic epilepsies.

An upcoming program aimed at evaluating treatments for genetic skin conditions.

South Korea

Asia

Spark Therapeutics is a biotechnology company focused on gene therapy for genetic diseases.

Spark Therapeutics

Moderna is a biotechnology company specializing in mRNA technology for vaccines and therapeutics.

Moderna

Rome Therapeutics is a biotechnology company focused on leveraging the dark genome for drug discovery.

Rome Therapeutics

Actio Biosciences is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and autoimmune diseases. The company leverages its proprietary drug discovery platform to target the LXR (Liver X Receptor) and ROR (Retinoic Acid Receptor-Related Orphan Receptor) pathways, which are involved in regulating immune responses and are implicated in various diseases.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 16, 2024 8:24 AM	78d775d7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:09 AM	5f390ff2
crunchbase profile	general	Nov 25, 2024 9:47 AM	90728cf1
li profile	general	May 16, 2024 8:24 AM	10aab787
translate crunchbase fundingrounds	general	Nov 25, 2024 2:04 PM	e554a3e7
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ACTIOBIOSCIENCES

Actio Biosciences